New antibody combo aims to tame rare blood disease
NCT ID NCT04754945
First seen Feb 22, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This early-phase trial tests whether adding the drug isatuximab to standard chemotherapy can safely treat people with high-risk AL amyloidosis, a rare disease where abnormal proteins damage organs. Eleven participants will receive the combination to see if it reduces toxicity and improves disease control. The goal is to find a better upfront therapy for this aggressive form of the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University
New York, New York, 10032, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 39322, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
UT Southwestern
Dallas, Texas, 75390, United States
-
University of California
Orange, California, 92868, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Isatuximab (a monoclonal antibody) combined with bortezomib and cyclophosphamide
What this could lead to
If it works, this could offer a safer, more effective upfront treatment for high-risk AL amyloidosis, potentially improving disease control and survival.
What could go wrong
This is a very early (Phase 1) trial with only 11 participants, so results may not apply broadly. The treatment may still cause serious side effects or fail to control the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.